Figure 6.

IID enhances IIP activity. (A) RP-HPLC elution profiles of the soluble products after treatment of unlabeled PG with IIP and the indicated IID mutants. The tetrapeptide product is shown schematically. (B) Coomassie-stained gel of purified proteins. The extracellular domains of wild-type IID and five IID mutants are shown. (C) Analysis of IIP activity in the presence of the IID mutants using the RBB dye release assay. All reactions with IID and IIP contained 1 μM each protein. The lysozyme reaction contained 4 μM protein.